Lab Med Online.  2021 Jan;11(1):1-10. 10.47429/lmo.2021.11.1.1.

Standards and Guidelines for Reporting Diagnostic Test Results in Acute Leukemia Patients: Bone Marrow Examination, Flow Cytometry, and Cytogenetic/Molecular Genetics Tests

• Bang HI
• Kim IS
• Park SH
• Lee ST
• Hwang SM
• Huh J
• Huh HJ
• Song J
• Park R
• Lee YJ
• Kim Y
• Kong SY
• The Committee for Standardization in Korean Society for Laboratory Hematology

• KMID: 2525774
• DOI: http://doi.org/10.47429/lmo.2021.11.1.1

Abstract

Reports on hematological neoplasms are produced in various formats in different laboratories. For best patient care, standardization of reports adopting a format that provides concise and clear information is necessary. To this end, the Diagnostic Hematology Standardization Committee, organized by the Korean Society for Laboratory Hematology, has proposed a standardized format for reporting diagnostic test results for acute leukemia patients. It is hoped that this standardization will broadly improve communication with clinicians and improve patient care.

Keyword

Standardization; Report; Acute leukemia; Bone marrow; Flow cytometry; Genetics

Figure

• 

  Fig. 1 Sample bone marrow report for a patient diagnosed with acute myeloid leukemia, PML-RARA according to consensus guidelines.

• 

  Fig. 2 Sample leukemia/lymphoma flow cytometric immunophenotyping report for a patient diagnosed with B-lymphoblastic leukemia according to consensus guidelines.

• 

  Fig. 3 Sample minimal residual disease flow cytometric immunophenotyping report for a patient receiving follow up care for B-lymphoblastic leukemia, according to consensus guidelines.

• 

  Fig. 4 Sample chromosome analysis report for a patient diagnosed with acute myeloid leukemia, PML-RARA according to consensus guidelines.

• 

  Fig. 5 Sample FISH report for a patient with KMT2A rearrangement according to consensus guidelines.

• 

  Fig. 6 Sample gene mutation test report for a patient with CEBPA mutation according to consensus guidelines.

• 

  Fig. 7 Sample BCR-ABL1 real-time quantitative PCR test report for a patient according to consensus guidelines.

• 

  Fig. 8 Sample Hemavision, multiplex nested RT-PCR test report for a patient according to consensus guidelines.

• 

  Fig. 9 Sample next-generation sequencing test report for a patient according to consensus guidelines.

Reference

1. Swerdlow SH, Campo E, editors. 2017. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. International Agency for Research on Cancer;Lyon, France:

2. Sever C, Abbott CL, de Baca ME, Khoury JD, Perkins SL, Reichard KK, et al. 2016; Bone marrow synoptic reporting for hematologic neoplasms: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 140:932–49. DOI: 10.5858/arpa.2015-0450-SA. PMID: 26905483.

3. Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC. 2008; ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 30:349–64. DOI: 10.1111/j.1751-553X.2008.01100.x. PMID: 18822060.

4. Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, et al. 2007; 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 72:S14–22. DOI: 10.1002/cyto.b.20363. PMID: 17803189.

5. Clinical and Laboratory Standards Institute. 2007. Clinical flow cytometric analysis of neoplastic hematolymphoid cells;Approved guideline-Second edition. CLSI document H43-A2. Clinical and Laboratory Standards Institute;Wayne, PA:

6. Claustres M, Kožich V, Dequeker E, Fowler B, Hehir-Kwa JY, Miller K, et al. 2014; Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). Eur J Hum Genet. 22:160–70. DOI: 10.1038/ejhg.2013.125. PMID: 23942201. PMCID: PMC3895644.

7. Mikhail FM, Heerema NA, Rao KW, Burnside RD, Cherry AM, Cooley LD. 2016; Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities. Genet Med. 18:635–42. DOI: 10.1038/gim.2016.50. PMID: 27124785.

8. Kwon JA, Kim YG, Park G, Kim JM, Cho YU, Huh J, et al. 2019; Recommendation for the peripheral blood cell morphology report. Lab Med Online. 9:115–25. DOI: 10.3343/lmo.2019.9.3.115.

9. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. 2016; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.

10. Béné M, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, et al. 2011; Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 25:567–74. DOI: 10.1038/leu.2010.312. PMID: 21252983.

11. Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. 2017; Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 129:347–57. DOI: 10.1182/blood-2016-07-726307. PMID: 27903527. PMCID: PMC5291958.

12. Wood BL. 2016; Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 90:47–53. DOI: 10.1002/cyto.b.21239. PMID: 25906832.

13. Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J, et al. 2018; Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 131:1275–91. DOI: 10.1182/blood-2017-09-801498. PMID: 29330221. PMCID: PMC5865231.

14. Rack KA, van den Berg E, Haferlach C, Beverloo HB, Costa D, Espinet B, et al. 2019; European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia. 33:1851–67. DOI: 10.1038/s41375-019-0378-z. PMID: 30696948. PMCID: PMC6756035.

15. McGowan-Jordan J, Simons A, Schmid M. 2016; ISCN: an international system for human cytogenomic nomenclature (2016). Cytogenetic and Genome Research. 149:Basel, Switzerland;1–2.

16. Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, et al. 2018; Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. Br J Haematol. 182:777–88. DOI: 10.1111/bjh.15542. PMID: 30125955. PMCID: PMC6175193.

17. Ohgami RS, Arber DA. 2013; Challenges in consolidated reporting of hematopoietic neoplasms. Surg Pathol Clin. 6:795–806. DOI: 10.1016/j.path.2013.08.001. PMID: 26839198.

18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. 2015; Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17:405–24. DOI: 10.1038/gim.2015.30. PMID: 25741868. PMCID: PMC4544753.

19. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. 2017; Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 19:4–23. DOI: 10.1016/j.jmoldx.2016.10.002. PMID: 27993330. PMCID: PMC5707196.